RDH11

Across TCGA pan-cancer cohorts, RDH11 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated RDH11 data layer compared with 26 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher RDH11 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated RDH11 expression acts as an unfavorable survival marker.

BLCA, UCEC, and SKCM are the cancer types where RDH11 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	All	0.052	0.688	<.001	30	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SKCM	OS	Median	All	0.482	0.787	.046	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

RDH11–BLCA (OS)

Open the BLCA breakdown →